Toni K. Choueiri, MD, on Clear Cell RCC: Treatment With Belzutifan Plus Cabozantinib

February 17, 2021 By The ASCO Post Staff

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuses a preliminary phase II analysis of the HIF-2a inhibitor belzutifan in combination with cabozantinib, which showed antitumor activity in previously treated patients with metastatic clear cell renal cell carcinoma (Abstract 272).

Related Content